IgA肾病与肾脏、心血管事件及死亡风险
美国大型医疗系统内纳入1651例经活检确诊的IgA肾病成人,按年龄性别匹配非肾小球性CKD及无CKD对照,多变量Cox模型比较至2021年的结局。IgA肾病较非肾小球性CKD的ESKD、CKD恶化及AKI风险更高,心血管事件与死亡无显著差异;较无CKD者心衰住院和死亡风险显著更高。
要点
- IgA肾病较非肾小球性CKD的ESKD风险高(aHR 2.79),CKD恶化风险高(aHR 3.05)。
- IgA肾病较无CKD者心衰住院风险高(aHR 8.06),死亡风险高(aHR 2.90)。
- IgA肾病与非肾小球性CKD的心血管事件和死亡风险无显著差异。
核心结论
- IgA肾病成人较非肾小球性CKD肾脏不良结局风险更高,较无CKD者心衰和死亡风险显著更高。
研究设计与样本
- 回顾性队列研究,应用自然语言处理在电子健康记录中识别2010–2020年活检确诊IgA肾病成人1651例。
- 另设年龄性别匹配的非肾小球性CKD组(n=9863)和无CKD组(n=16510),随访至2021年。
- 采用多变量Cox比例风险模型比较ESKD、CKD恶化、AKI、心血管结局及死亡。
主要发现
- IgA肾病患者平均年龄43岁,48%女性,41%亚裔或太平洋岛民,3.3%黑人。
- 较非肾小球性CKD,IgA肾病ESKD的aHR为2.79(95%CI 2.16-3.62),CKD恶化aHR为3.05(95%CI 2.68-3.46),AKI的aHR为1.45(95%CI 1.22-1.73)。
- 较非肾小球性CKD,IgA肾病心血管事件和死亡无显著调整差异。
- 较无CKD者,IgA肾病心衰住院aHR为8.06(95%CI 2.90-22.37),死亡aHR为2.90(95%CI 2.08-4.02)。
- 较无CKD者,IgA肾病急性心梗或卒中/短暂性脑缺血发作无显著差异。
临床怎么用
- IgA肾病患者应加强肾脏结局监测与干预,尤其关注ESKD和CKD恶化风险。
- 对IgA肾病患者需警惕心衰和死亡风险,即使相较无CKD人群也应重视心血管评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Few population-based data exist in the U.S. about adults with IgA nephropathy (IgAN) and risks of kidney, cardiovascular, and mortality outcomes versus those with nonglomerular chronic kidney disease (CKD) or without CKD. METHODS: We applied natural language processing (NLP) algorithms to electronic health record (EHR) data within a large integrated healthcare delivery system to identify adults with biopsy-proven IgAN between 2010 and 2020. We next identified 2 separate comparison cohorts of adults with nonglomerular CKD and adults without CKD matched on age and sex, and compared the rates of end-stage kidney disease (ESKD), worsening CKD, acute kidney injury (AKI), cardiovascular outcomes, and death through 2021 using multivariable Cox proportional hazards models. RESULTS: We identified 1651 adults with biopsy-confirmed IgAN who had a mean age of 43 years and 48% women, 41% Asian or Pacific Islander, and 3.3% Black. Compared with matched adults with nonglomerular CKD (n = 9863), those with IgAN had higher adjusted rates of ESKD (adjusted hazard ratio [aHR]: 2.79, 95% CI: 2.16-3.62), worsening CKD (aHR: 3.05, 95% CI: 2.68-3.46), and AKI (aHR: 1.45, 95% CI: 1.22-1.73) but no significant adjusted differences in cardiovascular events and death. Compared with matched adults without CKD (n = 16,510), patients with IgAN had substantially higher adjusted rates of adverse kidney outcomes as well as higher adjusted rates of hospitalization for heart failure (aHR: 8.06, 95% CI: 2.90-22.37) and death (aHR: 2.90, 95% CI: 2.08-4.02) but not acute myocardial infarction or stroke/transient ischemic attack. CONCLUSION: Adults with IgAN are at greater risk of adverse kidney outcomes versus nonglomerular CKD and substantially higher risks of heart failure and death compared with no CKD.
引用
- Go AS, Tan TC, Mahapatra A, et al. IgAN and Risks of Kidney and Cardiovascular Events and Death. Kidney Int Rep. 2026. PMID: 42027552. doi:10.1016/j.ekir.2026.106501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。